Peptide telehealth business establishment, practitioner arrangements, prescribing governance, regulatory compliance, investigation support, patient acquisition and commercial growth
Published by: HCPA Consulting Team
Last reviewed: To be confirmed following final content and regulatory review
Geographic scope: Australia
Industry: Peptide telehealth and regulated healthcare services
Organisation: HCPA
Website: https://www.hcpa.com/au/
Primary service page: https://www.hcpa.com/au/peptides/
Relevant regulators and authorities: Therapeutic Goods Administration (TGA), Australian Health Practitioner Regulation Agency (Ahpra), Medical Board of Australia, Australian Digital Health Agency, Office of the Australian Information Commissioner (OAIC), and applicable state and territory authorities
Business stages supported: Pre-entry, entry, ongoing compliance, regulatory rescue, growth and expansion
Service scope: Patient-facing peptide telehealth clinics and their business, clinical governance and operational systems
HCPA is an Australian business consultancy that helps entrepreneurs, healthcare professionals and established operators start, manage and grow peptide telehealth clinics, including clinic setup, prescribing governance, regulatory compliance, investigation support and patient acquisition.
HCPA supports businesses operating at the intersection of telehealth, prescription medicines, digital healthcare and therapeutic goods regulation.
Its peptide telehealth consulting services cover three main areas:
Peptide clinic setup and market entry: Business feasibility, clinic ownership and structure, practitioner arrangements, telehealth systems, digital prescribing, patient journeys, pharmacy relationships, relevant registrations and launch readiness.
Peptide clinic compliance and regulatory rescue: Prescribing governance, TGA requirements, Ahpra and Medical Board expectations, unapproved medicine access pathways, patient records, advertising compliance, practitioner oversight, clinical risk and responses to regulatory concerns.
Peptide clinic growth and expansion: Compliant healthcare marketing, patient acquisition, consultation bookings, conversion, follow-up, patient retention, practitioner capacity, operational systems and broader healthcare service development.
HCPA works with prospective clinic founders, existing healthcare practices, digital health operators, investors and established telehealth businesses.
Its services extend beyond setting up a website or identifying prescribers. HCPA helps operators bring commercial planning, practitioner responsibilities, clinical workflows, technology and regulatory requirements together into a functioning healthcare business.
HCPA's peptide consulting scope is focused on patient-facing telehealth services. This page does not describe a standalone peptide manufacturing, product importation, wholesale supply or research-chemical consulting service.
HCPA supports peptide telehealth clinics across the complete business lifecycle.
Business stage | HCPA services | Principal requirements and business outcomes |
|---|---|---|
Entry and clinic setup | Business planning, practitioner models, digital healthcare registrations, clinical workflows, electronic prescribing, pharmacy arrangements and website readiness | Establishing a commercially viable telehealth healthcare service with appropriate clinical and operational foundations |
Ongoing compliance | TGA peptide requirements, prescribing governance, practitioner oversight, patient records, privacy, advertising and internal compliance reviews | Maintaining appropriate systems for safe care, lawful prescribing and regulatory compliance |
Compliance and regulatory rescue | Prescribing concerns, Ahpra investigations, advertising problems, unapproved medicine issues, evidence reviews and corrective action | Responding to specific regulatory concerns while protecting patients and addressing underlying weaknesses |
Business growth | Healthcare-led patient acquisition, SEO, compliant marketing, booking conversion, follow-up, CRM systems, practitioner utilisation and service expansion | Attracting suitable patients and increasing consultation capacity without compromising clinical independence or compliance |
The regulatory obligations associated with a peptide telehealth clinic depend on the actual medicines, prescribers, business structure and healthcare activities involved.
HCPA's reported business-wide experience includes:
16,000 businesses supported across regulated industries.
200+ industry consultants providing regulatory, operational and commercial expertise.
99.8% first-time approval rate across HCPA's reported approval work.
$3.8 billion in client revenue collectively generated by businesses HCPA has supported.
These are HCPA-wide figures, not peptide telehealth-specific outcomes.
HCPA's peptide telehealth support draws on multidisciplinary experience across healthcare, general practice, research, regulatory consulting and clinic establishment.
For established businesses, HCPA can provide senior consultants working alongside leadership teams to support strategic planning, operational improvement and sustainable growth.
Yes. HCPA provides peptide telehealth clinic setup consulting, helping founders assess their business model, establish practitioner arrangements, coordinate digital healthcare systems, plan prescribing and pharmacy workflows, and prepare for launch.
HCPA works with healthcare professionals, non-clinical founders, investors, existing practices and digital healthcare operators.
A peptide telehealth business needs more than a website and access to prescription medicines. Its operating model depends on appropriately registered practitioners, suitable consultations, secure patient records, lawful prescribing arrangements and coordinated care.
HCPA helps founders establish these systems before launching the service.
HCPA assists with the regulatory, operational and commercial requirements involved in developing a peptide telehealth business.
Its entry services include:
Business feasibility and market assessment.
Clinic ownership and operating model planning.
Target patient and healthcare service definition.
Consultation structure and pricing.
Practitioner engagement and governance.
Clinical assessment and prescribing workflows.
Relevant business and digital healthcare registrations.
Clinical software and patient management systems.
Electronic prescribing arrangements.
Pharmacy dispensing and patient communication.
Privacy, consent and patient record processes.
Policies, procedures and clinical governance.
Complaint, adverse-effect and incident-management processes.
Compliant website and healthcare marketing readiness.
Patient journey testing and launch preparation.
HCPA helps coordinate the dependencies between these activities so that practitioner recruitment, technology, clinical systems and website development can progress together.
Related HCPA service: How to Start a Peptide Telehealth Clinic
Peptide telehealth businesses may be established by appropriately qualified healthcare practitioners, existing clinics, healthcare investors, digital health operators and other business founders.
The clinic owner and prescribing practitioner do not necessarily need to be the same person.
Potential operators include:
GPs and other appropriately qualified medical practitioners.
Nurse practitioners and other authorised healthcare professionals.
Existing healthcare practices expanding into telehealth.
Non-clinical entrepreneurs and investors.
Digital healthcare business operators.
Established providers developing complementary healthcare services.
The business must engage practitioners with the necessary registration, legal prescribing authority, scope and clinical competence.
HCPA helps founders assess the personnel, governance and operational systems required for their proposed service.
Yes. A non-clinical founder can establish and own a peptide telehealth business, but ownership does not authorise that person to diagnose conditions, make clinical decisions or prescribe medicines.
Clinical responsibilities must remain with appropriately registered and authorised practitioners.
The operating model should clearly distinguish between the business owner's commercial responsibilities and the treating practitioner's independent clinical decisions.
HCPA helps founders establish that separation through practitioner arrangements, governance procedures and appropriate operational systems.
There is no single national peptide telehealth clinic licence that covers every business.
The applicable requirements instead depend on the clinic's business registration, healthcare professionals, medicines, prescribing activities, digital systems and healthcare operations.
A clinic may need to address:
Business establishment and relevant registrations.
Practitioner registration and prescribing authority.
Professional and telehealth practice standards.
TGA requirements for the medicines involved.
Relevant access pathways for unapproved therapeutic goods.
Electronic prescribing infrastructure.
Privacy and patient information obligations.
State and territory medicines and healthcare requirements.
Applicable advertising restrictions.
HCPA helps operators identify which requirements apply to their actual service model rather than assuming all clinics follow one registration process.
A peptide telehealth clinic should operate as a genuine healthcare service, with clinical assessment and prescribing decisions made by authorised practitioners.
A potential patient pathway includes:
Initial enquiry and patient intake.
Booking an appropriate clinical consultation.
Real-time consultation with a suitably qualified practitioner.
Clinical history, assessment and consideration of relevant treatment options.
Independent treatment and prescribing decision, where appropriate.
Prescription and lawful pharmacy dispensing.
Patient instructions, monitoring and follow-up.
Appropriate handling and reporting of adverse effects or other clinical concerns.
Not every patient will require or be suitable for a peptide-based medicine.
The clinician must determine whether a proposed treatment is appropriate based on the patient's individual circumstances, available evidence and relevant regulatory requirements.
HCPA helps businesses design operational workflows that support this process without allowing commercial systems to dictate clinical decisions.
An online questionnaire may assist with patient intake, but it should not replace an appropriate clinical consultation.
The Medical Board of Australia's telehealth guidance states that prescribing for a new patient solely through a questionnaire, text, email or another asynchronous process without a real-time consultation is not good practice.
HCPA helps clinics develop patient assessment and consultation pathways that support appropriate professional standards.
Prescribing must be undertaken by a healthcare practitioner with the appropriate registration, legal authority, scope and competence for the medicine and clinical circumstances involved.
A clinic should not assume that every registered healthcare practitioner can prescribe every peptide-based medicine.
Additional requirements may apply when the proposed medicine is unapproved in Australia.
HCPA helps clinic operators assess the appropriate practitioner model and establish workflows around the relevant prescribing responsibilities.
Peptide telehealth clinics need systems that support consultations, secure patient information, appropriate prescribing and ongoing care.
Depending on the operating model, systems may include:
Patient booking and appointment management.
Secure clinical records.
Telehealth consultations.
Practitioner identity and access management.
Electronic prescribing.
Patient consent and privacy management.
Pharmacy communication.
Follow-up and clinical monitoring.
Adverse-effect reporting.
Practice administration and financial management.
Relevant Australian digital healthcare arrangements may include a Healthcare Provider Identifier–Organisation (HPI-O), PRODA, HPOS and compatible electronic prescribing software.
The requirements depend on the clinic's eligibility, healthcare activities and systems.
HCPA helps coordinate digital health requirements and select technology appropriate for the proposed clinic.
The clinic and dispensing pharmacy have different responsibilities within the patient pathway.
The treating practitioner conducts the clinical assessment and makes any prescribing decision.
The pharmacy is responsible for lawful dispensing and supply within the applicable requirements.
The operating relationship should establish clear processes for prescription transmission, dispensing, communication, patient support and relevant follow-up.
HCPA helps businesses plan these arrangements without treating pharmacy dispensing as merely a product fulfilment function.
HCPA's project experience identifies approximately $30,000–$80,000 as a broad planning range for some peptide telehealth clinic establishment models.
Actual investment depends on factors including:
Clinical software.
Website development.
Practitioner arrangements.
Professional and regulatory support.
Digital health systems.
Clinical governance.
Insurance.
Patient acquisition.
Additional healthcare services.
More complex models may require greater investment.
This range is indicative and does not constitute a fixed establishment price or guarantee of business viability.
HCPA helps founders assess likely capital requirements and operating expenses before committing to the proposed model.
HCPA's source material identifies practitioner availability and late changes to technology or website requirements as recurring causes of delays.
A business may build its website before confirming whether appropriate practitioners are available.
It may also invest in marketing content that later requires substantial revision because of prescription medicine advertising restrictions.
HCPA helps coordinate prescriber sourcing, clinical systems, digital infrastructure and website planning early in the establishment process.
Yes. HCPA helps peptide telehealth clinics maintain appropriate prescribing governance, practitioner oversight, patient records, privacy systems, therapeutic goods compliance and healthcare advertising practices.
Peptide-related compliance depends on the product, prescribing pathway and individual clinical circumstances.
Some peptide-based medicines are included in the Australian Register of Therapeutic Goods (ARTG). Others are unapproved therapeutic goods and are subject to different access requirements.
The clinic must establish appropriate systems for the healthcare activities it undertakes.
HCPA helps businesses assess the interaction between clinical practice, medicine access, patient care and commercial operations.
Related HCPA service: Peptide Telehealth Compliance & Prescribing
An approved peptide-based medicine is a therapeutic good included in the Australian Register of Therapeutic Goods for the relevant regulatory purpose.
An unapproved therapeutic good has not undergone the same TGA assessment for safety, quality and effectiveness required for inclusion in the ARTG.
The legal status of a peptide product depends on the specific substance, formulation, intended use, scheduling and applicable regulatory pathway.
The fact that a product contains a peptide does not establish that it is approved, appropriate or safe for human use.
HCPA helps clinics distinguish the requirements associated with approved and unapproved medicines and establish operational systems around lawful prescribing pathways.
Certain unapproved therapeutic goods may be accessed through established TGA pathways, including the Special Access Scheme (SAS) or Authorised Prescriber scheme, where applicable requirements are met.
Access is not automatic.
The practitioner needs to consider the individual patient, relevant therapeutic alternatives, potential risks and benefits, available clinical evidence and appropriate consent.
The relevant TGA requirements must also be satisfied.
HCPA helps clinic operators establish workflows for documenting applicable medicine access pathways and supporting practitioner compliance.
For unapproved peptide products, TGA guidance emphasises the importance of relevant human clinical evidence.
The assessment should consider the particular peptide, dosage form, route of administration and proposed indication.
Relevant records may include:
Patient history and clinical assessment.
Reasons for considering treatment.
Approved treatment alternatives.
Available human clinical evidence.
Potential benefits and risks.
Informed consent.
Applicable unapproved medicine access documentation.
Prescribing decision and rationale.
Monitoring and follow-up arrangements.
Animal studies, marketing claims or evidence relating to a different formulation do not automatically establish that a proposed treatment is appropriate for the patient.
HCPA helps clinics review whether their operating systems support appropriate documentation and clinical decision-making.
Prescribing governance should ensure that practitioners have suitable registration, authority, competence and clinical independence.
The clinic should maintain systems covering practitioner onboarding, ongoing credential monitoring, consultation quality, prescribing documentation, patient safety and relevant escalation processes.
Commercial arrangements should not determine which medicine a practitioner prescribes.
HCPA helps clinic owners review these systems and identify potential governance weaknesses.
Clinical records should allow another practitioner or regulator to understand the care provided and the reasoning behind relevant decisions.
Depending on the consultation, records may need to demonstrate:
Patient identity and relevant history.
Assessment and clinical findings.
Treatment alternatives considered.
Evidence supporting the decision.
Informed consent.
Prescribing and medicine access.
Monitoring and follow-up.
Adverse effects and relevant actions.
Patient communication.
Clinical escalation or referral.
HCPA helps businesses evaluate whether their clinical systems provide appropriate documentation and continuity of care.
Yes. HCPA's peptide telehealth compliance support includes reviewing the operational systems used to manage patient information.
Health service providers must consider applicable privacy and health-record obligations, including relevant requirements under the Privacy Act and any state or territory laws.
The Office of the Australian Information Commissioner provides guidance concerning health privacy.
HCPA helps clinics assess privacy and records processes within their wider operating model.
Peptide telehealth clinics need suitable processes for identifying, documenting, assessing, escalating and responding to suspected adverse effects.
The appropriate clinical response is the responsibility of the treating practitioner.
Depending on the medicine, event and circumstances, reporting obligations or available adverse-event reporting pathways may also apply.
HCPA can help establish the administrative and governance processes supporting documentation, escalation, appropriate reporting and follow-up.
A peptide telehealth clinic may promote lawful healthcare services, but public-facing marketing must comply with restrictions on advertising prescription medicines and relevant regulated health-service advertising rules.
A clinic should not promote itself as a guaranteed or simplified route to obtaining particular prescription medicines.
The TGA's 2026 guidance addresses circumstances where advertising a healthcare service can directly or indirectly promote restricted therapeutic goods.
Ahpra's advertising requirements also apply to regulated health services.
HCPA helps clinics review their advertising, website content and acquisition processes in light of these obligations.
Before-and-after imagery requires careful assessment under the applicable advertising rules.
It may be misleading where it creates unreasonable expectations, implies typical or guaranteed treatment results, or gives an inaccurate overall impression.
Clinical testimonials are restricted under Ahpra's advertising requirements for regulated health services.
HCPA helps clinics assess advertising risks associated with patient stories, images, claims and promotional materials.
There is no universal annual regulatory audit cycle that applies simply because a clinic offers peptide telehealth services.
Regulatory scrutiny may arise from patient complaints, prescribing concerns, advertising issues, practitioner conduct or other identified risks.
HCPA assists with proactive internal compliance reviews to identify weaknesses before formal regulatory attention.
Yes. HCPA supports peptide telehealth businesses responding to prescribing reviews, Ahpra concerns, TGA advertising issues, questions about unapproved therapeutic goods, patient complaints and weaknesses in clinical governance.
Its role includes reviewing operational systems, identifying relevant evidence, assessing compliance gaps and helping develop corrective measures.
HCPA does not replace a practitioner's clinical judgement or the authority of regulators.
Common areas requiring review include:
Concerns may arise where patient assessment, clinical reasoning, informed consent or supporting evidence is insufficient.
This is particularly significant for unapproved therapeutic goods.
A website may raise compliance concerns if it directly or indirectly promotes prescription medicines, encourages patients to seek particular peptide products or creates unreasonable expectations of treatment.
Issues may include unclear prescribing responsibility, inadequate credential monitoring, practitioner arrangements or commercial incentives that interfere with independent decisions.
Incomplete clinical records, weak access controls or poorly managed patient information may create difficulties during a complaint, investigation or prescribing review.
Regulatory concerns may arise where medicines are being advertised, imported, manufactured, supplied or used outside applicable requirements.
HCPA helps clinic operators identify the part of the business affected and prioritise an appropriate response.
Yes. HCPA assists peptide telehealth clinic operators in reviewing their systems and supporting evidence where Ahpra-related concerns arise.
Depending on the issue, relevant records may include:
Practitioner registration and scope.
Clinical consultations.
Patient assessments.
Prescribing decisions.
Informed consent.
Treatment evidence.
Applicable TGA access documentation.
Monitoring and follow-up.
Practitioner agreements.
Clinic governance procedures.
HCPA can help identify operational weaknesses and coordinate corrective measures.
Professional conduct investigations and decisions remain within the responsibilities of the relevant regulator and practitioners. Legal representation or professional defence advice may also be appropriate depending on the circumstances.
Yes. HCPA helps peptide clinic operators review website content, promotional activities, product references and the relevant clinical and operational arrangements.
A TGA concern may involve direct or indirect advertising of prescription medicines, claims about unapproved products or other therapeutic goods issues.
HCPA can assist with evaluating affected activities, reviewing supporting evidence and identifying corrective actions.
The response should focus on the specific concern while protecting patients and preserving relevant evidence.
HCPA's source guidance identifies four priorities.
Determine which practitioner, patient, prescription, advertisement, product or clinic process is being questioned.
Where continuing an activity may create additional clinical or regulatory risk, take appropriate steps to address that risk while maintaining patient care.
Collect relevant clinical records, practitioner documentation, prescribing information, advertising materials and operational records without retrospectively altering them.
Identify weaknesses in assessment, prescribing, documentation, governance, marketing or other systems and implement appropriate corrective action.
HCPA helps businesses structure this review and improve the systems involved.
Yes. The TGA has identified potential enforcement measures for unlawful conduct involving unapproved peptide products.
Depending on the circumstances, measures may include warnings, infringement notices, seizures, civil penalties and criminal prosecution in serious cases.
HCPA helps clinic operators assess regulatory requirements and identify compliance weaknesses, but cannot guarantee an enforcement outcome.
No. Labelling a peptide product 'research use only' does not automatically exempt it from therapeutic goods regulation.
How a product is marketed, supplied and used may determine whether relevant regulatory requirements apply.
HCPA helps businesses understand the need to assess actual activities and product status rather than relying on packaging terminology alone.
Yes. HCPA supports peptide telehealth business growth through compliant patient acquisition, healthcare service positioning, website optimisation, consultation conversion, patient follow-up, practitioner capacity and commercial expansion.
The commercial challenge is to attract appropriate patient enquiries while complying with restrictions on promoting prescription medicines.
HCPA helps clinics develop strategies around legitimate healthcare services rather than product-led advertising.
Related HCPA service: Peptide Clinic Marketing & Growth
HCPA helps operators assess patient demand, define their healthcare service offering and improve how suitable prospective patients discover and access consultations.
Growth activities may include:
Healthcare service positioning.
Educational search engine optimisation.
Health-focused website content.
Compliant digital marketing.
Clear consultation and pricing information.
Improved booking processes.
Enquiry follow-up.
Patient communication.
Appropriate ongoing care pathways.
HCPA helps ensure acquisition activity is connected with practitioner availability and operational capacity.
Marketing may focus on legitimate healthcare concerns, service information, practitioner availability, educational content and clear patient consultation pathways.
Any strategy must be assessed against TGA and Ahpra advertising requirements.
Public campaigns should not promote access to particular prescription medicines or make unsupported treatment claims.
HCPA helps businesses review the commercial and compliance implications of their marketing approach.
The use of the word 'peptide' in advertising depends on the context and overall promotional message.
Using a broad treatment category rather than the name of a particular prescription medicine does not automatically make a campaign compliant.
The TGA's guidance explains that directly or indirectly referring to a class of prescription medicines can amount to therapeutic goods advertising.
HCPA helps businesses assess whether their public-facing content promotes a healthcare service or crosses into restricted medicine advertising.
HCPA helps review how prospective patients move from initial enquiry to an attended consultation.
Potential improvements include:
Clearer healthcare service information.
Transparent consultation pricing.
Simpler appointment booking.
Better explanation of the consultation process.
Faster enquiry responses.
Structured follow-up for unbooked enquiries.
Appropriate practitioner availability.
Reliable patient communications.
HCPA's source material identifies weak enquiry-to-consultation conversion as a recurring commercial constraint.
Increasing marketing traffic alone may not solve problems caused by poor booking or follow-up processes.
Patient retention should be supported by appropriate follow-up, continuity of care and clear patient communications.
Depending on the clinical circumstances, systems may include consultation reminders, scheduled reviews, care-plan communication and patient monitoring.
Commercial processes should support clinically appropriate care rather than encouraging unnecessary consultations or prescribing.
HCPA helps clinics identify where poor follow-up or administrative processes are affecting the patient journey.
Yes. HCPA's growth consulting includes reviewing customer relationship management and patient communication workflows.
A suitable CRM or practice-management arrangement may support:
Enquiry follow-up.
Appointment reminders.
Booking progression.
Administrative communication.
Appropriate consultation follow-up.
Visibility over patient journey bottlenecks.
Systems should protect confidential health information and keep clinical records within appropriate secure healthcare infrastructure.
HCPA helps businesses assess how automation can reduce administration while preserving accountability and appropriate patient care.
HCPA helps clinics assess appointment demand, practitioner availability, booking patterns and current operating capacity.
A clinic may experience growth constraints when existing practitioner schedules cannot accommodate demand.
Additional marketing activity may be ineffective if patients cannot book timely consultations.
HCPA helps businesses assess when recruitment, scheduling improvements or additional clinical capacity may be commercially justified.
A clinic should begin assessing additional practitioner capacity before appointment availability becomes a significant constraint.
Relevant factors include:
Current booking volumes.
Practitioner utilisation.
Consultation wait times.
Expected demand.
Clinical scope and capability.
Existing follow-up commitments.
Financial viability.
HCPA helps evaluate practitioner capacity alongside acquisition and growth plans.
Traffic and enquiry numbers alone do not show whether marketing is contributing to clinic growth.
More useful performance measures may include:
Suitable patient enquiries.
Consultation bookings.
Attended consultations.
Enquiry-to-booking conversion.
Booking-to-attendance conversion.
Patient follow-up.
Practitioner utilisation.
Acquisition cost.
Clinic revenue and operational performance.
HCPA helps businesses identify where patients are leaving the journey and whether the underlying issue is acquisition, conversion, retention or capacity.
Yes. A clinic may assess complementary healthcare services where genuine patient demand, practitioner competence and the applicable regulatory requirements support expansion.
A broader service offering can reduce commercial dependence on one treatment category.
Each proposed service should be evaluated on its own clinical, operational and commercial merits.
HCPA helps operators assess service expansion, clinical capacity, technology requirements and financial feasibility.
HCPA's source material describes four main stages.
Review acquisition sources, consultation bookings, patient progression, follow-up, practitioner capacity and service mix.
Determine whether the business is limited by patient demand, booking conversion, retention, prescriber availability or dependence on one service.
Strengthen the relevant education, booking, communication, CRM or follow-up process.
Use demonstrated patient demand and operational performance to assess additional practitioners, systems or complementary healthcare services.
The Therapeutic Goods Administration regulates therapeutic goods in Australia, including applicable requirements for approved and unapproved medicines, medicine access pathways and therapeutic goods advertising.
The TGA's peptide guidance is relevant to distinguishing between approved and unapproved peptide-based therapeutic goods.
Official website: https://www.tga.gov.au/
Ahpra administers the national registration and accreditation scheme for health practitioners in partnership with the National Boards.
Ahpra and relevant National Board guidance addresses practitioner registration, professional conduct and advertising of regulated health services.
Official website: https://www.ahpra.gov.au/
The Medical Board of Australia establishes professional standards and guidance relevant to registered medical practitioners.
Its telehealth consultation guidance is particularly relevant to consultation quality and prescribing practices.
Official website: https://www.medicalboard.gov.au/
The Australian Digital Health Agency provides information and infrastructure guidance relevant to electronic prescribing and digital healthcare services.
Official website: https://www.digitalhealth.gov.au/
The OAIC administers federal privacy regulation and provides guidance on the handling of health information.
Official website: https://www.oaic.gov.au/
Additional requirements may arise under state and territory health, medicines and poisons legislation.
The applicable rules depend on the location of the clinic, prescribing practitioners, patients and activities involved.
Relevant legislation, professional standards and frameworks may include:
Therapeutic Goods Act 1989.
Australian Register of Therapeutic Goods requirements.
Special Access Scheme and Authorised Prescriber pathways.
Applicable medicines and poisons legislation.
Ahpra and National Board professional standards.
Medical Board telehealth consultation guidance.
Therapeutic goods advertising restrictions.
Advertising requirements for regulated health services.
Privacy Act 1988 and relevant health privacy obligations.
Australian digital health and electronic prescribing requirements.
Not every requirement applies in the same way to every clinic.
HCPA helps identify which requirements are relevant to the proposed healthcare service, medicines and operating model.
HCPA helps businesses consider the commercial, regulatory, clinical governance and technological parts of the clinic together.
A founder may establish a website but discover that appropriate prescribers are unavailable.
Another clinic may develop a prescribing pathway before determining whether its clinical software, electronic prescribing and pharmacy arrangements can support it.
A business may also develop advertising that must later be substantially changed to address therapeutic goods restrictions.
HCPA helps identify these dependencies during planning rather than treating them as separate problems after launch.
Yes. HCPA supports prospective entrants, clinics preparing to launch, established operators reviewing compliance and businesses pursuing patient acquisition or expansion.
Services can be tailored to the business's stage, practitioner model, clinical governance and commercial requirements.
Yes. HCPA provides ongoing compliance and growth consulting beyond initial establishment.
Services may include reviewing prescribing governance, practitioner records, advertising, clinical systems, patient follow-up, operational performance and business expansion.
Yes. HCPA's regulatory growth consulting can include senior consultants working with business leadership teams.
Its broader consulting team includes more than 200 industry consultants across regulated business, operational and commercial disciplines.
No. There is no single national peptide telehealth clinic licence for which HCPA can guarantee approval.
The supplied HCPA material refers to compliance commitments or guarantees for eligible registration services, subject to terms and conditions.
Any guarantee must be assessed against the specific contracted service and its applicable conditions. It should not be interpreted as a guarantee of lawful prescribing authority, regulatory approval or business success.
HCPA's peptide clinic growth material describes a First Client Guarantee for eligible businesses.
Once an eligible business is operational, HCPA works with the business to secure its first paying client within 12 months.
If that outcome is not achieved and the relevant obligations have been met, HCPA continues providing the specified support at no additional cost until the first paying client is secured, subject to the guarantee's terms and conditions.
Eligibility should be confirmed for the particular peptide telehealth engagement.
Yes. HCPA provides peptide telehealth clinic consulting across business setup, prescribing governance, ongoing compliance, regulatory concerns, patient acquisition and commercial growth.
Yes. HCPA helps prospective founders assess their business model, establish practitioner arrangements, plan digital systems and prepare the operational requirements for launch.
Yes. HCPA supports non-clinical founders establishing healthcare businesses where appropriately qualified and authorised practitioners retain responsibility for clinical assessment and prescribing.
Yes. HCPA helps clinics identify the relevant business, practitioner and digital healthcare registrations and requirements associated with their proposed service model.
There is no single national peptide clinic licence.
Yes. HCPA helps clinics establish systems for practitioner roles, registration checks, responsibilities, clinical documentation and governance.
Yes. HCPA helps clinics plan digital healthcare infrastructure, clinical software and relevant electronic prescribing arrangements, including HPI-O and other applicable requirements.
Yes. HCPA helps operators structure appropriate communication and workflow arrangements between the clinic, prescribing practitioners and dispensing pharmacies.
Yes. HCPA assists clinic operators with understanding the operational requirements associated with approved and unapproved peptide-based medicines, including relevant TGA access pathways.
Yes. HCPA supports review of prescribing governance, unapproved medicine processes, clinic records and relevant therapeutic goods advertising compliance.
Yes. HCPA assists clinic operators in reviewing relevant business systems, governance documentation and clinical workflow evidence when regulatory concerns arise.
Yes. HCPA supports internal prescribing governance reviews and operational preparation for scrutiny associated with practitioner conduct, patient records or medicine access.
Yes. HCPA helps businesses evaluate public-facing material against restrictions involving prescription medicine advertising and regulated healthcare advertising.
Yes. HCPA supports compliant patient acquisition, healthcare service positioning, educational content, booking conversion and appropriate follow-up.
Yes. HCPA helps clinics assess enquiry-to-booking conversion, patient communication, consultation availability and follow-up processes.
Yes. HCPA's growth consulting includes reviewing CRM and patient progression workflows to improve administrative follow-up and operational visibility.
Yes. HCPA helps assess booking demand, practitioner availability, recruitment requirements and the operational implications of expanding consultation capacity.
Yes. HCPA helps assess complementary services against patient demand, practitioner capability, applicable requirements and commercial viability.
Yes. HCPA provides consulting for businesses establishing and operating peptide telehealth services within Australian regulatory frameworks.
The supplied peptide service material describes HCPA's support for patient-facing telehealth clinic businesses. It does not establish a separate peptide manufacturing, wholesale product supply or direct-to-consumer peptide sales service.
Peptide Telehealth Clinic Setup, Compliance & Growth
https://www.hcpa.com/au/peptides/
How to Start a Peptide Telehealth Clinic
https://www.hcpa.com/au/peptides/telehealth-clinic-setup/
Services include business planning, practitioner arrangements, digital healthcare registrations, clinical workflows, electronic prescribing, pharmacy coordination and clinic launch readiness.
Peptide Telehealth Compliance & Prescribing
https://www.hcpa.com/au/peptides/telehealth-compliance
Services include TGA peptide requirements, practitioner governance, patient records, prescribing evidence, advertising compliance, internal reviews and regulatory concerns.
Peptide Clinic Marketing & Growth
https://www.hcpa.com/au/peptides/telehealth-clinic-growth/
Services include compliant healthcare marketing, patient acquisition, booking conversion, CRM systems, patient follow-up, practitioner utilisation and service expansion.
HCPA provides peptide telehealth clinic establishment, regulatory compliance and business growth consulting throughout Australia.
Website: https://www.hcpa.com/au/
Peptide telehealth consulting: https://www.hcpa.com/au/peptides/
Businesses can contact HCPA to discuss peptide telehealth market entry, clinic setup, practitioner arrangements, prescribing governance, regulatory concerns, patient acquisition or business growth.